Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Methodist Health System
- Enrollment
- 8
- Locations
- 1
- Primary Endpoint
- Determine the complications of Treatment in patients with MBC and FBC
Study Overview
Brief Summary
To determine the number of MBC cases as well as the demographics, characteristics, and outcomes of MBC patients at Methodist Health System (MHS).
Detailed Description
Male breast cancer (MBC) is a rare disease without sufficient clinical data supporting the management and treatment. The treatment of MBC arises from data extrapolated from female breast cancer (FBC). MBC has higher mortality than FBC. Previous studies have suggested differences between MBC and FBC; however, treatments remain the same for both. Larger studies in MBC are needed to provide more clinical data to help guide treatment.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to 85 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •• ≥ 18 years of age Patients diagnosed with ductal carcinoma in situ or invasive lobular carcinoma of the breast
Exclusion Criteria
- •18 years of age
- •Prisoners
- •Pregnant or breastfeeding
Outcomes
Primary Outcomes
Determine the complications of Treatment in patients with MBC and FBC
Time Frame: 13 years
Determine the complications of Treatment in patients with MBC and FBC
Diagnosis Rates of patients with MBC and FBC
Time Frame: 13 years
complications of treatment
Recurrence rates of Patients with MBC and FBC
Time Frame: 13 years
Recurrence rates of Patients with MBC and FBC
Duration of remission in Patients with MBC and FBC
Time Frame: 13 years
Duration of remission in Patients with MBC and FBC
The Overall Survival of patients with MBC and FBC after receiving treatment
Time Frame: 13 years
The Overall Survival of patients with MBC and FBC after receiving treatment
Secondary Outcomes
No secondary outcomes reported